Epigenetic deregulation in myeloid malignancies.

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Epigenetic deregulation is a hallmark of cancer, particularly myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
• Distinct epigenetic profiles characterize different subtypes of myeloid disorders, reflecting their underlying biological heterogeneity.
• Mutations in epigenetic-modifying enzymes are frequently observed in these malignancies, highlighting their crucial role in disease development and progression.

Purpose of the Study:

• To review the role of epigenetic deregulation in leukemic transformation.
• To explore the potential of targeting epigenetic modifiers as a therapeutic strategy for myeloid malignancies.

Main Methods:

• This review synthesizes current research on epigenetic alterations in leukemia.
• It examines the link between genetic mutations in epigenetic enzymes and disease phenotypes.
• The review discusses the therapeutic implications of targeting epigenetic modifiers.

Main Results:

• Abnormal epigenetic patterning is a universal feature of myeloid cancers.
• Specific epigenetic profiles correlate with distinct myeloid disorder subtypes.
• Inhibition of aberrant epigenetic modifiers shows potential for reversing leukemic landscapes.

Conclusions:

• Epigenetic deregulation is critical in the initiation, progression, and outcome of myeloid malignancies.
• Aberrant epigenetic modifiers represent viable targets for novel drug design in leukemia therapy.